Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

|Videos|January 3, 2023

Expert discusses what is on the horizon for stone disease in coming years

Author(s)Urology Times staff

“As people think about how we can do stone surgery more effectively, less morbidly for our patients, and less invasively, I think we're going to see robots enter our picture,” says Thomas Chi, MD.

In this interview, Thomas Chi, MD, predicts what might be on the horizon for stone disease in the coming years, and he discusses some of his own research interests within the field. Chi is a professor and associate chair at the University of California, San Francisco.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Residual stone volume outperforms stone-free rate as risk marker

ByBrett Johnson, MD

July 17th 2026

Amy E. Krambeck, MD, on choosing between CVAC and FANS for suction-based ureteroscopy

ByAmy E. Krambeck, MD

July 10th 2026

Study links unmet social needs with worse stone-specific quality of life

ByMichael John Mari Talagsa Uy, MD

July 6th 2026

From OR to office: How Break Wave changes urology practice workflow

ByBen H. Chew, MD, MSc

July 3rd 2026

Economic analysis: SURE reduces downstream stone costs

ByBrett Johnson, MD

July 1st 2026

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC

Individualizing androgen pathway therapy in mCSPC

Testosterone deficiency: FAQs from the AUA guideline

BOND-003 Cohort C: Efficacy Results

Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer